Entries by LRuas

ImaginAb Announces new Clinical Trial at Hull University Teaching Hospitals NHS Trust to Investigate CD8 ImmunoPET in Patients with Renal Cancer and Malignant Melanoma

/in

Los Angeles, California, USA, December 6th, 2022 – ImaginAb Inc., a global biotechnology company focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent and radiopharmaceutical therapy (RPT) products, today announces the start of a Phase II clinical trial at Hull University Teaching Hospitals NHS Trust in the UK. The trial, named PRETZCEL, will investigate ImaginAb’s […]

ISA Completes Enrolment in Randomized Double Blind Phase 2 Clinical Trial of ISA101b in HPV16 induced Oropharyngeal Cancer

/in

Study designed to investigate the efficacy and safety of ISA101b added to checkpoint inhibitor therapy in Human Papilloma Virus type 16 (HPV16) induced oropharyngeal cancer (OPC). Trial is part of an extensive clinical development program for ISA101b in a collaboration with Regeneron. Top line interim results anticipated in third quarter of 2023. Oegstgeest, 30 November […]

NXI Therapeutics Expands Management Team and Board Ahead of Next Growth Stage

/in

Experienced life sciences executive Dr Ruben Herrendorff appointed as CEO Serial biotech entrepreneur Dr Ulf Grawunder appointed as Board member Targeted therapy aims to treat autoimmune disease whilst avoiding serious, long-term complications of the current non-selective immunosuppression 30 November 2022, Basel, Switzerland – NXI Therapeutics[1], the specialist biotech developing next generation immunosuppressive drugs for autoimmune […]

© Optimum Strategic Communications.